Page 2 - Mark Litton News Today

16.11.2022 - Fosgonimeton treatment showed results suggestive of neuroprotection and potential disease modification in models of Parkinson’s disease Small molecule positive modulators of HGF/MET improved symptoms of diabetic neuropathy with a persistent ... Seite 1

PHILADELPHIA, Oct. 16, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Athira Pharma, Inc. (“Athira” or the “Company”)...

Additional data showed numerical improvement in activities of daily living (ADCS-ADL23), a protocoled secondary endpoint and a functional measure of...

Additional data showed numerical improvement in activities of daily living , a protocoled secondary endpoint and a functional measure of independence Plasma biomarker data in a pre-specified... | August 3, 2022

An Alzheimer’s disease drug from Athira Pharma has failed a Phase 2 clinical trial and the biotech has a surprising theory why. Athira says standard of care drugs Alzheimer’s patients are already taking may diminish the effect of its small molecule and this finding could inform how the company proceeds with an ongoing Phase 3 clinical trial.

BOTHELL, Wash., May 19, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Sends Letter to Athira’s Shareholders Seeking Replacement of CEO Dr. Mark LittonHighlights New Management and Shareholder Centric Directors Are Required to Provide Proper Oversight of ATH-1017 Clinical Trials to Maximize Likelihood of SuccessUrges ATHA Shareholders to VOTE the BLUE Proxy Card NEW YORK--(BUSINESS WIR...

Athira Pharma is circling the wagons and urging shareholders to reject investor Richard Kayne's calls for a management change.

By Svea Herbst-Bayliss BOSTON (Reuters) - Billionaire investor Richard (Ric) Kayne is seeking two board seats at Athira Pharma, arguing the biotech co...